NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Ce... (ties. The Company's actual results inclu...)

HOME >> BIOLOGY >> TECHNOLOGY

NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.

Date:10/27/2008

ties. The Company's actual results, including any successful development of its adult stem cell collection network and any successful development of its VSEL technology into therapies, could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Contact:

NeoStem, Inc.

Robin Smith, Chief Executive Officer

T: 212-584-4180

E: rsmith@neostem.com

http://www.neostem.com

SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
2. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
3. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
4. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
5. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
6. NeoStem to Expand Stem Cell Collection Center Network to Florida
7. NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells
8. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
9. NeoStem to Present at Third Annual Stem Cell Summit in New York City
10. NeoStem Announces NY State License for Adult Stem Cell Collection
11. Transave, Inc. Secures $12.5 Million in New Financing

Post Your Comments:

(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food

(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot

(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx

(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur

Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4 Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2 Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3 Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4 Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5 Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2 Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2

[0] BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year [0] Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced [0] Martek to Announce Fourth Quarter and Fiscal Year 2009 Results [0] Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures

...ewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:...io of therapeutic,proteins for metabolic and cardi...gible to proceed with its planned Phase I/II human... the 30-day review period of its,Investigational N...bmitted,the application in July to the U.S. Food a...

...ins momentum with launch of a Phase ...LE, Md., Sept. 16 Novavax, Inc.,(Nasdaq: NVAX ) ...in a Phase,II clinical trial of its virus-like par...Phase IIa randomized, placebo controlled clinical ...of different doses of its seasonal,influenza VLP v...

...l/ - MIGENIX Inc. (the,"Company" or "MIGENIX") (TS... drugs for infectious diseases, reports financial ...nd provides a corporate update on its programs,and...AMS, Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226;...related infections): Cadence Pharmaceuticals, Inc....

Other Biology Technology:SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2 SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3 Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2 Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3 Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4 Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10 MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11

SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate MIGENIX Reports First Quarter Fiscal 2009 Financial Results

(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou

(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t

(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege

Breaking Biology News(10 mins):How nutrition affects healthy aging 2 New therapy targets for amyloid disease 2 Papillomavirus silences innate immune response 2 Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 1 Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 2 Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 3 Traumatic brain injury caused by exposure to explosive blast presents critical challenge 49434 1 Traumatic brain injury caused by exposure to explosive blast presents critical challenge 49434 2 Antibiotics take toll on beneficial microbes in gut 8909 1 Antibiotics take toll on beneficial microbes in gut 8909 2 Antibiotics take toll on beneficial microbes in gut 8909 3

[0] How nutrition affects healthy aging [0] New therapy targets for amyloid disease [0] Papillomavirus silences innate immune response

... PLAIN, N.Y., JULY 27, 2008 In a new March of Dim...tentially deadly disorder that affects about 5 per...s in mice that may have important implications for....D., Ph.D., and Rodney E. Kellems, Ph.D., Departme...n M. Ramin, M.D., Department of Obstetrics, Gyneco...

...MINGHAM, Ala. The life expectancy for patients wi...d by more than 13 years since the late 1990s thank...ding to researchers at the University of Alabama a...Vancouver, British Columbia. , Improved survival ... among 43,355 HIV-positive study participants in E...

...GO (July 25, 2008) New research published in the ... of Surgeons shows elevated plasma DNA is a relia...dy also suggests that plasma DNA levels rise befor...jority of patients. , Esophageal cancer, one of...usually diagnosed at a late stage. An accurate mar...

Other Biology News:New research on pre-eclampsia in mice may have important implications for humans 2 Anti-HIV therapy boosts life expectancy more than 13 years 2 Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds 2

New research on pre-eclampsia in mice may have important implications for humans Anti-HIV therapy boosts life expectancy more than 13 years Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds

Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc

Rabbit Anti-Raf1 Polyclonal Antibody, Unconjugated from Abcam

Sheep Anti-Human hCG beta core fragment Polyclonal Antibody, Unconjugated from Abcam

Mouse Anti-SIT Monoclonal Antibody, Unconjugated, Clone SIT-01 from Abcam

Biology Products:

Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc Rabbit Anti-Raf1 Polyclonal Antibody, Unconjugated from Abcam Sheep Anti-Human hCG beta core fragment Polyclonal Antibody, Unconjugated from Abcam Mouse Anti-SIT Monoclonal Antibody, Unconjugated, Clone SIT-01 from Abcam

NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Ce...(ties. The Company's actual results inclu...)